These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 20460471)

  • 1. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.
    Jönsson G; Busch C; Knappskog S; Geisler J; Miletic H; Ringnér M; Lillehaug JR; Borg A; Lønning PE
    Clin Cancer Res; 2010 Jul; 16(13):3356-67. PubMed ID: 20460471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
    Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
    Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
    Saldanha G; Potter L; Daforno P; Pringle JH
    Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.
    Lee JH; Choi JW; Kim YS
    Br J Dermatol; 2011 Apr; 164(4):776-84. PubMed ID: 21166657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
    Colombino M; Capone M; Lissia A; Cossu A; Rubino C; De Giorgi V; Massi D; Fonsatti E; Staibano S; Nappi O; Pagani E; Casula M; Manca A; Sini M; Franco R; Botti G; Caracò C; Mozzillo N; Ascierto PA; Palmieri G
    J Clin Oncol; 2012 Jul; 30(20):2522-9. PubMed ID: 22614978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes.
    Bloethner S; Hemminki K; Thirumaran RK; Chen B; Mueller-Berghaus J; Ugurel S; Schadendorf D; Kumar R
    Melanoma Res; 2006 Aug; 16(4):297-307. PubMed ID: 16845325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
    Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
    J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are all melanomas the same? Spitzoid melanoma is a distinct subtype of melanoma.
    Lee DA; Cohen JA; Twaddell WS; Palacios G; Gill M; Levit E; Halperin AJ; Mones J; Busam KJ; Silvers DN; Celebi JT
    Cancer; 2006 Feb; 106(4):907-13. PubMed ID: 16421887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular classification of melanoma using real-time quantitative reverse transcriptase-polymerase chain reaction.
    Lewis TB; Robison JE; Bastien R; Milash B; Boucher K; Samlowski WE; Leachman SA; Dirk Noyes R; Wittwer CT; Perreard L; Bernard PS
    Cancer; 2005 Oct; 104(8):1678-86. PubMed ID: 16116595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
    Griewank KG; Westekemper H; Murali R; Mach M; Schilling B; Wiesner T; Schimming T; Livingstone E; Sucker A; Grabellus F; Metz C; Süsskind D; Hillen U; Speicher MR; Woodman SE; Steuhl KP; Schadendorf D
    Clin Cancer Res; 2013 Jun; 19(12):3143-52. PubMed ID: 23633454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of galectin-3 expression with melanoma progression and prognosis.
    Brown ER; Doig T; Anderson N; Brenn T; Doherty V; Xu Y; Bartlett JM; Smyth JF; Melton DW
    Eur J Cancer; 2012 Apr; 48(6):865-74. PubMed ID: 22071132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.
    Devitt B; Liu W; Salemi R; Wolfe R; Kelly J; Tzen CY; Dobrovic A; McArthur G
    Pigment Cell Melanoma Res; 2011 Aug; 24(4):666-72. PubMed ID: 21615881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
    Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
    Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KIT pathway alterations in mucosal melanomas of the vulva and other sites.
    Omholt K; Grafström E; Kanter-Lewensohn L; Hansson J; Ragnarsson-Olding BK
    Clin Cancer Res; 2011 Jun; 17(12):3933-42. PubMed ID: 21680547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
    Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
    J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiling of primary cutaneous melanoma.
    Winnepenninckx V; Van den Oord JJ
    Verh K Acad Geneeskd Belg; 2007; 69(1):23-45. PubMed ID: 17427873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas.
    Sviatoha V; Tani E; Ghaderi M; Kleina R; Skoog L
    Anticancer Res; 2010 Sep; 30(9):3267-72. PubMed ID: 20944096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF mutations in metastatic melanoma: a possible association with clinical outcome.
    Kumar R; Angelini S; Czene K; Sauroja I; Hahka-Kemppinen M; Pyrhönen S; Hemminki K
    Clin Cancer Res; 2003 Aug; 9(9):3362-8. PubMed ID: 12960123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.